1. Share Prices

  2. Oxford Biomedica PLC (OXB)

304.50p-3.00 (-0.98%)21 Mar 2025, 16:41
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Oxford Biomedica PLC Fundamentals

Company NameOxford Biomedica PLCLast Updated2025-03-21
IndustryBiotechnologySectorHealthcare
Shares in Issue105.975 mMarket Cap£322.69 m
PE Ratio20.62Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£1.63EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.4503Debt Equity Ratio1.5921
Asset Equity Ratio3.4396Cash Equity Ratio1.1431
Quick Ratio1.8353Current Ratio2.35
Price To Book Value4.8709ROCE0

Oxford Biomedica PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Oxford Biomedica PLC Company Financials

Assets20232022
Tangible Assets£75.69 m£133.78 m
Intangible Assets£30.98 m£105.89 m
Investments00
Total Fixed Assets£111.01 m£244.68 m
Stocks£12.87 m£12.63 m
Debtors£15.42 m£49.86 m
Cash & Equivalents£103.72 m£141.28 m
Other Assets£4.34 m£5.01 m
Total Assets£252.34 m£460.18 m
Liabilities20232022
Creditors within 1 year£44.31 m£59.66 m
Creditors after 1 year£130.19 m£164.32 m
Other Liabilities00
Total Liabilities£174.51 m£223.99 m
Net assets£77.83 m£236.19 m
Equity20232022
Called up share capital£48.40 m£48.13 m
Share Premium£380.33 m£379.95 m
Profit / Loss-£188.53 m-£45.98 m
Other Equity£74.01 m£204.65 m
Preference & Minorities£3.83 m£31.54 m
Total Capital Employed£77.83 m£236.19 m
Ratios20232022
Debt Ratio£0.59£0.35
Debt-to-Equity£1.46£0.54
Assets / Equity3.43963.4396
Cash / Equity1.14311.1431
EPS-£0.63-£0.41
Cash Flow20232022
Cash from operating activities-£28.52 m-£12.62 m
Cashflow before financing-£41.22 m£86.01 m
Increase in Cash-£38.41 m£29.55 m
Income20232022
Turnover£89.54 m£139.99 m
Cost of sales£49.81 m£70.81 m
Gross Profit£39.73 m£69.18 m
Operating Profit-£184.17 m-£30.22 m
Pre-Tax profit-£188.53 m-£45.98 m

Oxford Biomedica PLC Company Background

SectorHealthcare
ActivitiesOxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types.
Latest Interim Date23 Sep 2024
Latest Fiscal Year End Date29 Apr 2024

Oxford Biomedica PLC Directors

AppointedNamePosition
2012-04-30Mr. Andrew Brian WoodExecutive Director,Chief Financial Officer and Company Sec
2020-06-23Dr. Lorenzo Tallarigo, M.D.Non-Executive Director,Chairman
2016-01-05Mr. Daniel B. Soland Non-Executive Director
2024-12-31Ms. Leone D PattersonNon-Executive Director
2013-06-06Dr. Stuart Naylor, PhDExecutive Director,Chief Scientific Officer
2022-05-27Mr. John Andrew Dawson CBEExecutive Director,Chief Executive Officer
2011-01-10Dr. Alexander D LewisNon-Executive Director
2022-04-27Dr. Andrew John William HeathNon-Executive Director
2020-06-08Professor Alan John KingsmanNon-Executive Director,Chairman
2017-04-28Dr. Paul BlakeExecutive Director,Chief Development Officer
2018-06-29Mr. Peter J NolanExecutive Director,Chief Business Officer
2016-04-30Mr. Philip Nicholas RodgersNon-Executive Director
2011-08-09Mr. Nick WoolfInvestor Relation
2011-08-09Dr. Michael McDonaldExecutive Director,Chief Executive Officer
2024-04-30Dr. Roch F. DoliveuxNon-Executive Director,Chairman
2024-06-21Dr. Michael HaydenNon-Executive Director
2011-08-09Dr. Peter Johnson BSc,PhD,FRSC,FIBiol,FRCPathNon-Executive Director,Chairman
2011-08-09Professor Susan Mary Kingsman, M.A.,PhDExecutive Director
2018-04-26Mr. Timothy William Watts Non-Executive Director
2021-02-03Mr. Martin Henry Diggle Non-Executive Director
2024-10-04Dr. Frank MathiasExecutive Director,Chief Executive Officer
2024-04-30Dr. Heather Elizabeth Preston, M.D.Non-Executive Director
2024-04-30Mr. Stuart HendersonNon-Executive Director,Vice Chairman
2024-09-02Mr. Stuart PaynterExecutive Director,Chief Financial Officer
2024-06-21Ms. Catherine MoukheibirNon-Executive Director
2024-04-30Dr. Siyamak RastyNon-Executive Director
2024-04-30Professor Dame Kay DaviesNon-Executive Director,Senior Independent Director
2024-04-30Ms. Namrata P PatelNon-Executive Director
2024-10-04Ms. Lucinda CrabtreeExecutive Director,Chief Financial Officer

Oxford Biomedica PLC Contact Details

Company NameOxford BioMedica PLC
AddressWindrush Court, Transport Way, Oxford, OX4 6LT
Telephone+44 1865783000
Websitehttps://www.oxb.com

Oxford Biomedica PLC Advisors

StockbrokerWG Partners
Financial AdviserPeel Hunt LLP
Phone+44 2074188900
StockbrokerPeel Hunt LLP
Phone+44 2074188900
Remuneration ConsultantDeloitte LLP
Phone+44 2079363000
Fax+44 2075831198
Financial AdviserWG Partners LLP
Financial PR AdviserConsilium Strategic Communications
Phone+44 2037095700
BankBarclays Bank PLC
RegistrarLink Asset Services
Phone+44 8716640300
Fax+44 2086392342
SolicitorCovington & Burling LLP
Phone+44 2070672000
Fax +44 2070672222

Most Read

Receive our
daily news email

Subscribe to the latest investing news by entering your email address below

You can opt out at any time.

For five days a week you will get

  • The latest company news
  • Insight into investment trends
  • Round-up of director's buys and sells
  • Articles from Shares magazine
Sharesmagazine cover

Plus more useful investment content and occasional promotional offers.

Shares Magazine Latest Issue Cover
Latest Issue:
20 Mar 2025Subscribe now

Market Overview

UK 350 Risers and Fallers

Risers

CompanyPrice% Chg
Asos PLC301.8018.35
Bakkavor Group PLC171.505.86
Energean PLC872.503.68
Crest Nicholson Holdings PLC167.002.58
Oxford Nanopore Technologies PLC111.501.73
Harbour Energy PLC204.601.54

Fallers

CompanyPrice% Chg
Wood Group (John) PLC38.40-13.08
Ferrexpo PLC63.40-10.83
Wetherspoon ( J.D.) PLC541.00-9.38
Raspberry Pi Holdings PLC511.50-8.50
Firstgroup PLC168.70-7.31
Essentra PLC104.00-5.63
Risers/fallers data from previous trading day.